GPC3 and neoplasm: C-CAR031 is an autologous GPC3-directed CAR-T armored with dominant negative TGFβR2 that, in a phase 1 study with 24 patients that had been previously treated with systemic therapy, including ICI, demonstrated tumor reductions in 91% of patients, including a median reduction of 44% of extrahepatic lesions, and an ORR of 50% [131].